A current approach to the management of tuberculosis infection

Current Clinical Topics in Infectious Diseases

Volumn , Issue 20, 2000, Pages 209-231

  Jasmer, Robert M ^a   Small, Peter M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ETHAMBUTOL; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AIDS RELATED COMPLEX; FORECASTING; HUMAN; IMMUNOCOMPETENCE; MASS SCREENING; METHODOLOGY; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; TUBERCULIN TEST; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; BCG VACCINE; ETHAMBUTOL; FORECASTING; HUMANS; IMMUNOCOMPETENCE; ISONIAZID; MASS SCREENING; PATIENT COMPLIANCE; RIFAMPIN; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0034564536     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (80)

1. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-226.
2. Donin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994;72:213-220.
3. Sudre P, Ten Dam HG, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ 1992;70:149-159.
4. Cantwell MF, Snider DE Jr, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994;272:535-539.
5. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991;144:745-749.
6. Snider DR Jr, Roper WL. The new tuberculosis. N Engl J Med 1992;326:703-705.
7. McGowan JE Jr, Blumberg HM. Inner-city tuberculosis in the USA. J Hosp Infect 1995;30(suppl):282-295.
8. Tuberculosis morbidity - United States, 1997. MMWR 1998;47:253-257.
9. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City-turning the tide. N Engl J Med 1995;333:229-233.
10. Jasmer RM, Hahn JA, Small PM, et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999;130:971-978.
11. Ferebee SH. An epidemiologic model of tuberculosis in the United States. Bull Natl Tuberc Assoc 1967;53:4-7.
12. American Thoracic Society. The tuberculin skin test. Am Rev Respir Dis 1981;124:356-363.
13. Seibert FB, Glenn JT. Tuberculin purified derivative: preparation and analysis of a large quantity for standard. Am Rev Tuberc 1941;44:9-25.
14. Palmer CE, Edwards LB, Hopwood L, Edwards PG. Experimental and epidemiologic basis for the interpretation of tuberculin sensitivity. J Pediatr 1959;55:413-429.
15. Rust P, Thomas J. A method for estimating the prevalence of tuberculosis infection. Am J Epidemiol 1975;101:311-322.
16. Edwards PG, Edwards LB. Quantitative aspects of tuberculin sensitivity. Am Rev Respir Dis 1960;81:24-32.
17. Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis 1982;125(suppl):8-16.
18. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970;17:28-106.
19. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962;85:490-521.
20. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967;95:935-943.
21. Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis 1963;88:161-175.
22. Katz J, Kunofsky S, Damijonaitis V, et al. Effect of isoniazid upon the reactivation of inactive tuberculosis. Preliminary report. Am Rev Respir Dis 1965;91:345-350.
23. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO 1982;60: 555-564.
24. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-relatcd hepatitis. A U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:9991-10001.
25. Comstock GW, Edwards PQ. The competing risks of tuberculosis and hepatitis for adult tuberculin reactors. Am Rev Respir Dis 1975;111:573-577.
26. Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of isoniazid JAMA 1986;255:1579-1583.
27. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-1374.
28. Screening for tuberculosis and for tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1995;44 (RR-11):18-34.
29. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550.
30. Rieder HL, Cauthcn GM, Comstock GW, Snider DE Jr. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989;11: 79-98.
31. Anonucii G, Girardi E, Raviglione MC, et al. Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. JAMA 1995;274:143-148.
32. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992;326:231-235.
33. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced UIV infection. N Engl J Med 1993;328:1137-1144.
34. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514-1521.
35. Chaparas SD, Vandiviere H, Melvin J, et al. Tuberculin test. Am Rev Respir Dis 1985;132:175-177.
36. Kendig EI Jr, Kirkpatrick BV, Carter H, et al. Underreading of the tuberculin skin test. Chest 1998;113:1165-1177.
37. Reichman LB. A scandalous incompetence . . . continued. Chest 1998;113:1153-1154.
38. Rupp ME, Schultz AW Jr, Davis JC. Discordance between tuberculin skin test results with two commercial purified protein derivative preparations. J Infect Dis 1994;169:1174-1175.
39. Lamphear BP, Linnemann CC, Cannon CG. A high false-positive rate of tuberculosis associated with Aplisol. J Infect Dis 1994;169:703-704.
40. Grabau JC, DiFerdinando GT Jr, Novick LF. False positive tuberculin skin test results. Public Health Rep 1995;10:703-706.
41. Wurt R, Fernandez J, Jovanovic B. Real and apparent tuberculin skin test conversions in a group of medical students. Infect Control Hosp Epidemiol 1994;15:516-519.
42. Villarino ME, Burman W, Wang, Y-C, et al. Comparable specificity of two commercial tuberculin reagents in persons at low risk for tuberculous infection. JAMA 1999;281:169-171.
43. Thompson MJ, Glassroth JL, Snider DE Jr, Farer LS. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119:587-597.
44. Slutkin G, Perez-Stable EJ, Hopewell PC. Time course and boosting of tuberculin reactions in nursing borne residents. Am Rev Respir Dis 1986;134:1048-1051.
45. American Thoracic Society. Diagnostic standards and classification of tuberculosis. Am Rev Respir Dis 1990;142:725-735.
46. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;150:15-21.
47. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med 1971;285:1506-1509.
48. Bovornkitti P, Kangsadl P, Suthcrapat P, et al. Reversion and reconversion of tuberculin skin test reactions in correlation with the use of prednisone. Dis Chest 1960;38:51-55.
49. Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in persons with HIV infection. Am J Resp Crit Care Med 1996;153:1982-1984.
50. Markowitz N, Hansen MI, Wilkowshy T, et al. Tuberculin and anergy testing in HIV-seropositive individuals. Ann Intern Med 1993; 119:185-193.
51. Caiaffa WT, Graham NMH, Galai N, et al. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med 1995; 155:2111-2117.
52. Gordin F, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997;337:315-320.
53. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-808.
54. Centers for Disease Control. Anergy skin testing and preventive therapy for HIV-infected persons: Revised recommendations. MMWR 1997;46(RR-15):1-10.
55. Snider DE Jr. Bacille Calmette-Guerin vaccinations and tuberculin skin tests. JAMA 1985;253:3438-3439.
56. American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S1-S27.
57. Centers for Disease Control. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and recommendations. MMWR 1998;47(RR-20):1-58.
58. Nazar-Stewart V, Nolan CM. Results of a directly observed intermittent isoniazid preventive therapy program in a shelter for the homeless. N Engl J Med 1992;146:57-60.
59. Centers for Disease Control. Core curriculum on tuberculosis. What the clinician should know. 3rd ed. 1994.
60. Mitchell JR, Zimmennan HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976;84:181-192.
61. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995;333:1118-1127.
62. Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1000 patients. JAMA 1979; 241:1239-1241.
63. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy. A 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018.
64. Millard PS, Wiscosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med 1996;164:486-491.
65. Hawken MP, Meme HK, Elliot LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infectcd adults: results of a randomized controlled trial. AIDS 1997;11:875-882.
66. Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272.
67. Comstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis 1970;101:780-782.
68. Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-792.
69. Mwinga AG, Hosp M, Godrey-Fausett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-2457.
70. Graham NMH, Galai N, Nelson KE, et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med 1996;156:889-894.
71. Centers for Disease Control. Management of persons exposed to multidrug-resistant tuberculosis. MMWR 1992;41(RR-11)61-71.
72. Gordin F, Chaisson R, Matts J, et al. A randomized trial of 2 months of rifampin and pyrazinamide versus 12 months of isoniazid for the prevention of tuberculosis in HIV-positive, PPD-positive patients. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1998.
73. Bothamley GH. Serological diagnosis of tuberculosis. Eur Respir J 1995(suppl 20):676s-688s.
74. Streeton JA, Desem N, Jones SL. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 1998;2:443-450.
75. Behr MA, Wilson MA, Gill UT, et al. Comparative genomics of BCG vaccines by whole genome DNA microarray. Science 1999;284:1520-1523.
76. Arioli V, Berti M, Carniti G, et al. Antibacterial activity of DL473, a new semisynthetic rifamycin derivative. J Antibiotics 1981;34: 1026-1032.
77. Assandri A, Ratt B, Cristina T. Pharmacokinetics of rifapentine, a new long acting rifamycin, in the rat, the mouse, and the rabbit. J Antibiot 1984;37:1066-1075.
78. Biya Y, Lizhen Z, Fengying A. A clinical comparative study of Chinese-made rifapentine on chemotherapy of tuberculosis (follow-up results after 3 years), national cooperative group on the clinical study of rifapentine. Chinese J Antibiotics 1992;7:313-322.
79. Cooksey RC, Crawford JT, Jacobs WR Jr, Shinnick TM. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob Agents Chemother 1993;37:1348-1352.
80. Wilson M, DeRisi J, Kristensen H, et al. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Nat Acad Sci USA 1999;96:12833-12838.